Competition and substitutability in the Swedish pharmaceuticals market

Applied Economics

Volumn 35, Issue 14, 2003, Pages 1609-1617

  Rudholm, Niklas ^a  

^a UMEÅ UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG PRESCRIBING; INDUSTRIAL COMPETITION; PHARMACEUTICAL INDUSTRY; SUBSTITUTION;

SWEDEN;

EID: 0242414509     PISSN: 00036846     EISSN: None     Source Type: Journal    
DOI: 10.1080/0003684032000125042     Document Type: Article

References (25)

1. Andersson , R. G. and Thursby, J. G. (1986) Confidence intervals for elasticity estimators in translog models, Review of Economics and Statistics, 68, 647-57.
2. Aronsson, T., Bergman, M. A. and Rudholm, N. (2001) The impact of generic competition on brand name market shares-evidence from micro data, forthcoming in the Review of Industrial Organization, 19, 425-35.
3. Bae, J. P. (1997) Drug patent expirations and the speed of generic Entry, Health Services Research , 32, 87-101.
4. Ball, V. E. and Chambers, R. G. (1982) An economic analysis of technology in the meat products industry, American Journal of Agricultural Economics, 64, 699-709.
5. Barradell, L. B. and McTavish, D. (1993) Omeprazole - a pharmacoeconomic evaluation of its use in duodenal ulcer and reflux oesophagitis, PharmacoEconomics, 3, 482-510.
6. Baye, M. R., Maness, R. and Wiggins, S. N. (1997) Demand systems and the true subindex of the cost of living for pharmaceuticals, Applied Economics, 29, 1179-89.
7. Bernt, E. (1991) The Practice of Econometrics: Classic and Contemporary, Addison-Wesley Publishing Company, Reading, MA.
8. Bernt, E. and Wood, D. (1975) Technology, prices and the derived demand for energy, Review of Economics and Statistics, 57, 376-84.
9. Bernt, E. R., Bui, L., Reiley, D. R. and Urban, G. L. (1995) Information, marketing, and pricing in the US antiulcer drug market, American Economic Review, 85, 100-5.
10. Caves, R. E., Whinston, M. D. and Hurwitz, M. A. (1991) Patent expiration, entry, and competition in the US pharmaceutical industry. Brookings Papers on Economic Activity: Microeconomics, Vol. 1991, Brookings Institution, Washington, DC.
11. Chambers, R. G. (1988) Applied Production Analysis: A Dual Approach, Cambridge University Press, Cambridge.
12. Christensen, L. R. and Greene, W. (1976) Economies of scale in the US electric power generation, Journal of Political Economy, 84, 655-76.
13. Christensen, L. R., Jorgenson, D. W. and Lau, L. J. (1971) Conjugate duality and the transcendental logaritmic production function, Econometrica, 39, 255-6.
14. Ellison, S. F., Cockburn, I., Girilches, Z. and Hausman, J. (1997) Characteristics of demand for pharmaceutical products: an examination of four cephalosporins, RAND Journal of Economics, 28, 426-46.
15. Frank, R. G. and Salkever, D. S. (1997) Generic entry and the pricing of pharmaceuticals, Journal of Economics and Management Strategy, 6, 75-90.
16. Grabowski, H. G. and Vernon, J. M. (1992) Brand loyalty, entry and price competition in pharmaceuticals after the 1984 Drug Act, Journal of Law and Economics, 35, 331-50.
17. Heady, E. O. and Dillon, J. L. (1961) Agricultural Production Functions, Iowa State University Press, Ames, IA.
18. Hudson, J. (1992) Pricing dynamics in the pharmaceutical industry, Applied Economics, 24, 103-12.
19. Hurwitz, M. A. and Caves, R. E. (1988) Persuasion or information? Promotion and the market shares of brand name and generic pharmaceuticals, Journal of Law and Economics, 31, 299-320.
20. McElroy, M. B. (1987) Additive general error models for production, cost, and derived demand or share equations, Journal of Political Economy, 95, 737-57.
21. Rizzo, J. A. (1999) Advertising and competition in the ethical pharmaceutical industry: the case of antihypertensive drugs, Journal of Law and Economics, 42, 89-116.
22. Rudholm, N. (2001) Entry and the number of firms in the Swedish pharmaceuticals market, forthcoming in the Review of Industrial Organization, 19, 351-64.
23. Schwartzman, D. (1976) Innovation in the Pharmaceutical Industry, Johns Hopkins University Press, Baltimore, MD and London.
24. Scott Morton, F. M. (1999) Entry decisions in the generic pharmaceutical industry, Rand Journal of Economics, 30, 421-40.
25. Yu, S. S. (1984) Some determinants of entry into therapeutic drug markets, Review of Industrial Organization, 1, 260-75.